Immunotherapy reaches Breakthrough in eliminating HIV
Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based…
13/06/2016 - 3 minutes
HIV
The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection
CRISPR remains in the spotlight as the scientific discovery of the century. A long list…
29/03/2016 - 4 minutes
No, this French Startup didn’t Discover the Cure for HIV…
This is the story of a French doctor and his start-ups which have been trying to develop…
23/03/2016 - 3 minutes
How could the HIV Field benefit from Gilead’s new €2M Research Grants?
The US Giant Gilead is opening a new program of Grants to fund the next generation…
23/02/2016 - 3 minutes
Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital
MD Anderson (US) and the Berlin Biotech Mologen (Germany) have now partnered on for an Immuno-Oncology program fighting…
21/01/2016 - 2 minutes
A Phase II HIV Antiviral from France Has Promising Results
Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy…
13/01/2016 - 3 minutes
€100 Million Investment Round Prepares CureVac For Vaccine Expansion
"The RNA People" at CureVac in Tübingen (Germany) have a new €100M investment into their…
03/11/2015 - 2 minutes
CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!
One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening…
10/09/2015 - 3 minutes
InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine
HIV is definitely under the spotlight today. Just after Theravectys' announcement about its phase I/II success, InnaVirVax completed a…
20/07/2015 - 2 minutes
Theravectys’ HIV Cure on the Road to Success
Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic…
20/07/2015 - 3 minutes
Abivax launched an Euronext IPO to build up its anti-viral portfolio
Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech…
05/06/2015 - 1 minute
Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine
THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy,…
22/02/2015 - 3 minutes
